Merck launches anti-govt pill in Canada | The world

Merck, a pharmaceutical company known outside of North America as MSD, has announced the production of the molnupiravir tablet, an oral treatment against COVID-19, in Canada.

Merck Thermo Fisher Scientific, a Canadian company, has entered into an agreement to manufacture molecules that are not yet approved for use in any country in the world, according to a report from a manufacturing facility in the Canadian city of Whitby.

Tablets manufactured in VTP are prescribed for Canada, the United Kingdom, the European Union (EU), Asia and Latin America, when their use is approved by national authorities.

Merck The tablet, which will be developed in conjunction with Ridgeback Biotechnics, will be manufactured at only three facilities worldwide, he said.

On December 3rd, Canada Announced that it has entered into an agreement with Merck to purchase 500,000 molnupiravir therapies in 2022 with a further 500,000 purchase options.

Doug Ford, The Prime Minister of the Canadian province of Ontario, where the VTP plant is located, said the agreement guarantees Canada access to a key drug to combat COVID-19.

The Canadian government was criticized early in the epidemic for lack of domestic vaccine production, which caused severe supply problems for injections from Pfizer, Moderna and AstraZeneca in the first months of the immunization campaign.

In this sense, the agreement between Francois-Philippe Champagne, Canadian Minister of Innovation, Merck and Thermo Fisher is scientific. “Protect the domestic drug supply chain“Confirm Canada”Be better prepared for future health emergencies. “

Last week, Merck explained that its pill reduces the risk of death and hospitalization by 30%, which is one percent less than the 50% previously reported, but experts from the US Food and Drug Administration (FDA). The rest of the United States, which decided last Tuesday, said the results are positive for now and that its urgent use should be recognized.

In addition, the company said it should be equally effective in principle against any new variant of the virus on the same day.